Umbilical cord blood (UCB) has been an accepted source of hematopoietic stem cells (HSC) for transplantation for more than 30 years. Umbilical cord-derived stem cells are the youngest cells available for transfusion and yet their uptake lags behind bone marrow and peripheral blood-derived HSCs. Decreased engraftment rates and the low cell dose available for transplantation are limitations that are preventing umbilical cord blood-derived cells from reaching their full potential. While a handful of companies are now developing cord blood and tissue-derived cell therapeutics, it will likely take several years for these products to reach commercialization. [Read more…]
FUJIFILM Cellular Dynamics and Opsis Therapeutics Announce License with BlueRock Therapeutics for iPSC-derived Retinal Cell Therapy Candidate
MADISON, WI, January 23, 2024 — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics and co-founder David Gamm, M.D., Ph.D., focusing on developing cell therapies for patients with ocular diseases, today announced an agreement granting BlueRock Therapeutics (Cambridge, Mass.) an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases. BlueRock Therapeutics, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, exercised its option to exclusively license OpCT-001, an iPSC-derived photoreceptor cell therapy for human retinal diseases. [Read more…]
Bio-Techne Files Drug Master File For ExCellerate GMP iPSC Expansion Medium to Support Manufacture of Stem Cell Therapies
MINNEAPOLIS, MN, December 20, 2023 — Bio-Techne Corporation (NASDAQ: TECH) has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP), supporting the development and manufacture of regenerative medicine and stem cell therapies. [Read more…]
Pluri Inc. Launches the Latest Global Cell Therapy CDMO, PluriCDMO™
-
Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division.
-
PluriCDMO™ will help innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2 billion cell and gene therapy sector.
-
PluriCDMO™ includes Pluri’s well-established team as well as a Good Manufacturing Practice (GMP) facility and a state-of-the-art, proprietary bioreactor system enabling 3D cell expansion and supporting the manufacture of stem cells, Induced Pluripotent Stem Cells, Exosomes and Immuno therapeutics.
-
PluriCDMO™ will offer manufacturing support from the preclinical and development stages to late stage clinical and commercial production, including fill and finish and logistics.
-
Andy Lewin, an experienced CDMO executive, will head the new business division.
Recent Breakthroughs in Using Platelet-Rich Plasma (PRP) for Veterinary Applications
Platelet-rich plasma (PRP) therapy is blood plasma that has been enriched with platelets, using a process of standard whole blood collection, followed by anticoagulation (usually with citrate dextrose), and finally, centrifugation. This process separates the platelet-rich plasma (PRP) component of the blood from the red blood cells and other non-therapeutic components, producing a concentrated source of self-derived (“autologous”) platelets as the final PRP product.
This resulting PRP component contains both growth factors and cytokines that may have the ability to support or stimulate the healing of bone, as well as soft tissue structures, such as ligaments, tendons, fascia, and more. While there have not yet been large-scale, controlled clinical trials conducted to evaluate the efficacy of PRP, the procedure has nonetheless become commonplace in medical offices worldwide, most notably, within orthopedic offices. [Read more…]
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 334
- Next Page »




